
In patients with inflammatory bowel disease (IBD), use of the anti-TNF agent infliximab has been associated with reduced serological responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. 6,935 patients with IBD were recruited from 92 hospitals across the UK in the CLARITY study, and antibody responses to SARS-CoV-2 infection were examined in patients treated with infliximab or vedolizumab...
Like
Save
Share